ANTIBODIES TO OPGL

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

Antibodies to OPGL

ORGANIC CHEMISTRY

Immunoglobulins specific features-characterized by immunoglobulin fragments-F(ab')2

PEPTIDES 

MEDICAL OR VETERINARY SCIENCE; HYGIENE

Drugs for skeletal disorders-for non-specific disorders of the connective tissue

SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Drugs for immunological or allergic disorders

Medicinal preparations containing antigens or antibodies -Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum-against materials from animals-against proteinaceous materials, e.g. enzymes, hormones, lymphokines

PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 

Drugs for immunological or allergic disorders-Immunomodulators

Immunoglobulins specific features-characterized by immunoglobulin fragments-variable (Fv) region, i.e. VH and/or VL

Drugs for disorders of the blood or the extracellular fluid-Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock 

Immunoglobulins specific features-characterized by taxonomic origin-from primates, e.g. man

Medicinal preparations containing antigens or antibodies -Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum-against materials from animals-against normal tissues, cells

Immunoglobulins specific features-characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin-Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Medicinal preparations containing antigens or antibodies -comprising antibodies

Immunoglobulins specific features-characterized by non-natural combinations of immunoglobulin fragments-comprising only variable region components-Single chain antibody (scFv)

Drugs for immunological or allergic disorders-Immunomodulators-Immunosuppressants, e.g. drugs for graft rejection

Antineoplastic agents

Immunoglobulins specific features-characterized by immunoglobulin fragments-Complete heavy chain or Fd fragment, i.e. VH + CH1

Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Drugs for disorders of the metabolism -for electrolyte homeostasis-for calcium homeostasis 

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies -against material from animals or humans-against receptors, cell surface antigens or cell surface determinants-against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 

Drugs for disorders of the blood or the extracellular fluid

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies -against material from animals or humans-against cytokines, lymphokines or interferons-Tumor Necrosis Factors

Drugs for skeletal disorders-for bone diseases, e.g. rachitism, Paget's disease

Drugs for skeletal disorders-for bone diseases, e.g. rachitism, Paget's disease-for osteoporosis

Immunoglobulins specific features-characterized by immunoglobulin fragments-Fab or Fab'

Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00-Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Drugs for skeletal disorders

Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Drugs for skeletal disorders-for joint disorders, e.g. arthritis, arthrosis

Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Immunoglobulins specific features-characterized by immunoglobulin fragments-Complete light chain, i.e. VL + CL

Medicinal preparations containing antigens or antibodies -comprising antibodies-Comprising a combination of two or more separate antibodies

Immunoglobulins specific features-characterized by effect upon binding to a cell or to an antigen-Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Invalidity analysis

Prosecution analysis

Examiner search

General

Analytics

Cases

Patent Assignments

Citations